---
title: "The Danish stock market plummeted nearly 12%, Novo Nordisk fell 23%, dragging Zealand down about 7%, while the Italian banking sector rose over 2%"
description: "The Danish stock market plummeted nearly 12%, with Novo Nordisk's stock price crashing 23%, dragging Zealand Pharma down by about 7%. Meanwhile, the Italian banking sector rose by more than 2%. The Ge"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/250639885.md"
published_at: "2025-07-29T16:42:04.000Z"
---

# The Danish stock market plummeted nearly 12%, Novo Nordisk fell 23%, dragging Zealand down about 7%, while the Italian banking sector rose over 2%

> The Danish stock market plummeted nearly 12%, with Novo Nordisk's stock price crashing 23%, dragging Zealand Pharma down by about 7%. Meanwhile, the Italian banking sector rose by more than 2%. The German DAX 30 index increased by 1.03%, the French CAC 40 index rose by 0.72%, and the Italian FTSE MIB index climbed by 1.23%. The UK FTSE 100 index went up by 0.60%, while the FTSE 250 index fell by 0.72%

The German DAX 30 index closed up 1.03%, at 24,217.37 points.

The French CAC 40 index closed up 0.72%, at 7,857.36 points.

The Italian FTSE MIB index closed up 1.23%, at 41,234.31 points, and the FTSE Italia All-Share Banks index closed up 2.26%.

The UK FTSE 100 index closed up 0.60%, at 9,136.32 points, while the FTSE 250 index closed down 0.72%, and the FTSE 350 index closed up 0.45%.

The Danish OMX Copenhagen 20 index closed down 11.90%. According to Bloomberg data, only six of the 20 constituent stocks closed up, with Novo Nordisk down 23.11%, Zealand Pharma down 6.94%, followed closely by shipping giant A.P. Moller-Maersk Class B shares down 1.85%, renewable energy company Vestas Wind Systems down 1.83%, and Ørsted down 1.73%, ranking seventh from the bottom; the Copenhagen 25 index closed down 3.77%.

The Dutch AEX index closed up 0.21%

### Related Stocks

- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Puzo Michael J 在諾和諾德公司 $NVO 擁有價值 32 萬美元的股票持倉 | Puzo Michael J 在第三季度大幅減持了 Novo Nordisk A/S (NYSE:NVO) 的股份，減少幅度達到 86.9%，目前持有 5,775 股，價值 320,000 美元。其他機構投資者也調整了他們的持倉，True  | [Link](https://longbridge.com/en/news/276447697.md) |
| 諾和諾德公司董事會提議再次選舉 Lars Rebien Sorensen 擔任主席 | 諾和諾德公司董事會提議重新選舉拉斯·瑞比恩·索倫森為董事長 | [Link](https://longbridge.com/en/news/276440991.md) |
| 諾和諾德公司提議任命兩名新的董事會成員 | 丹麥製藥公司諾和諾德公司提議在 3 月 26 日於哥本哈根舉行的年度股東大會上新增三名董事會成員。提議的成員包括海倫娜·薩克森、揚·範·德·温克爾和拉莫娜·塞奎拉。薩克森此前已宣佈辭去 Sobi 的職務以加入諾和諾德。還提議重新選舉董事長拉 | [Link](https://longbridge.com/en/news/276442777.md) |
| 諾和諾德公司：將在 Ozempic 和 Wegovy 專利到期時準備好替代產品 - Berlingske | 丹麥製藥公司諾和諾德計劃在其藥物 Ozempic 和 Wegovy 的專利於 2031 年在歐洲和 2032 年在美國到期時，準備好替代藥物。研究負責人馬丁·霍爾斯特·朗格表示，某些臨牀試驗中的候選藥物可能會在 2030 年前提交審批。有關 | [Link](https://longbridge.com/en/news/276314777.md) |
| 諾和諾德公司獲得歐洲委員會批准使用更高劑量的 Wegovy 注射劑 | 2026 年 2 月 17 日東部時間上午 9:25（MT Newswires）-- 諾和諾德公司（NVO）週二表示，歐洲委員會已批准 Wegovy 的 7.2 毫克每週一次的維持劑量，適用於肥胖成年人。諾和諾德公司表示，此次批准是基於歐洲 | [Link](https://longbridge.com/en/news/276138110.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.